Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This research is designed to investigate whether the addition of fulvestrant 500mg to
anastrozole is better than anastrozole alone as first-line endocrine therapy for advanced
breast cancer.